vTv Therapeutics Inc. (VTVT): Business Model Canvas [Jan-2025 Updated]

In the dynamic landscape of biotechnology, vTv Therapeutics Inc. (VTVT) emerges as a pioneering force, strategically navigating the complex terrain of innovative drug development. By leveraging a sophisticated Business Model Canvas, this cutting-edge company is transforming the pharmaceutical research paradigm, focusing on breakthrough treatments for metabolic and inflammatory diseases that promise to address critical unmet medical needs. Their unique approach combines advanced scientific research, strategic partnerships, and precision medicine technologies, positioning vTv Therapeutics at the forefront of transformative healthcare solutions.

vTv Therapeutics Inc. (VTVT) - Business Model: Key Partnerships

Research Collaborations with Academic Institutions

As of 2024, vTv Therapeutics maintains research partnerships with the following academic institutions:

Institution	Research Focus	Collaboration Status
University of North Carolina	Alzheimer's Disease Research	Active Collaboration
Duke University	Type 2 Diabetes Therapeutic Development	Ongoing Research Partnership

Strategic Partnerships with Pharmaceutical Companies

vTv Therapeutics has established strategic pharmaceutical partnerships:

• Merck & Co. - Collaborative research agreement for diabetes therapeutics
• Novartis AG - Potential licensing discussions for inflammatory disease treatments

Contract Manufacturing Organizations

Current contract manufacturing partnerships include:

CMO Partner	Manufacturing Capability	Contract Value
Lonza Group Ltd.	Preclinical and Clinical Stage Manufacturing	$3.2 million annual contract
Catalent Pharma Solutions	Drug Formulation and Production	$2.7 million annual agreement

Licensing Agreements

Licensing agreements for therapeutic technologies:

• Exclusive licensing agreement with NIH for TTP399 glucose metabolism technology
• Non-exclusive licensing rights for GLP-1 receptor agonist platform

Total Partnership Investment in 2024: $6.5 million

vTv Therapeutics Inc. (VTVT) - Business Model: Key Activities

Biopharmaceutical Research and Development

vTv Therapeutics focuses on developing innovative therapeutic treatments with a specific emphasis on neurodegenerative diseases and metabolic disorders.

R&D Metric	2023 Data
Total R&D Expenditure	$14.3 million
Research Personnel	37 scientific staff
Active Research Programs	3 primary therapeutic areas

Clinical Trials for Novel Therapeutic Treatments

The company conducts targeted clinical trials across multiple therapeutic domains.

• Ongoing Phase 2 and Phase 3 clinical trials
• Focus on Alzheimer's disease and diabetes treatments
• Collaboration with external research institutions

Clinical Trial Category	Number of Active Trials	Estimated Investment
Alzheimer's Disease	2 trials	$8.7 million
Type 2 Diabetes	1 trial	$5.2 million

Drug Discovery and Molecular Engineering

vTv Therapeutics employs advanced molecular engineering techniques to develop innovative therapeutic compounds.

• Proprietary TTP platform for drug development
• Advanced computational modeling techniques
• Targeted molecular screening processes

Intellectual Property Management and Protection

Strategic management of intellectual assets is crucial for the company's competitive positioning.

IP Category	Total Count	Status
Active Patents	12 patents	Granted and Pending
Patent Applications	4 new applications	Under Review

vTv Therapeutics Inc. (VTVT) - Business Model: Key Resources

Proprietary Drug Development Platform

vTv Therapeutics utilizes a TTP-based drug discovery platform focused on neurodegenerative and inflammatory diseases.

Platform Characteristic	Specific Details
Technology Type	Targeting Protein (TTP) Platform
Primary Research Focus	Neurodegenerative and Inflammatory Conditions
Patent Portfolio	Multiple drug candidate patents

Experienced Scientific and Research Team

Key personnel with extensive biotechnology research backgrounds.

• Total Research Staff: Approximately 35-40 employees
• PhD-level Researchers: 60% of scientific team
• Average Industry Experience: 12-15 years

Clinical Trial Data and Research Insights

Comprehensive research database from multiple clinical trials.

Clinical Trial Metrics	Quantitative Data
Total Completed Trials	7-9 clinical stage programs
Active Clinical Trials	3-4 ongoing studies
Patient Enrollment	Approximately 500-700 total participants

Specialized Biotechnology Intellectual Property

Strong intellectual property portfolio protecting innovative drug development strategies.

• Total Active Patents: 12-15
• Patent Jurisdictions: United States, Europe, Japan
• Patent Expiration Range: 2030-2035

Financial Capital for Ongoing Research

Financial resources supporting continued drug development initiatives.

Financial Metric	Amount (USD)
Cash and Cash Equivalents (Q4 2023)	$28.4 million
Research and Development Expenses (2023)	$22.6 million
Net Loss (2023)	$37.2 million

vTv Therapeutics Inc. (VTVT) - Business Model: Value Propositions

Innovative Treatments for Metabolic and Inflammatory Diseases

vTv Therapeutics focuses on developing targeted therapies with specific focus on:

Disease Category	Key Therapeutic Targets	Development Stage
Type 2 Diabetes	TTP399 glucose control agent	Phase 2/3 clinical trials
Inflammatory Disorders	HPP737 inflammatory inhibitor	Preclinical development

Potential Breakthrough Therapies for Unmet Medical Needs

• Alzheimer's disease therapeutic approach targeting neuroinflammation
• Metabolic syndrome intervention strategies
• Precision medicine solutions for complex chronic conditions

Advanced Small Molecule Drug Development Approach

Drug Development Platform Characteristics:

Platform Feature	Technical Specification
Molecular Design	Proprietary small molecule screening technology
Research Methodology	Rational drug design using computational modeling

Targeted Therapeutic Solutions with Precision Medicine Focus

Therapeutic portfolio addressing specific patient populations:

• Personalized treatment algorithms
• Biomarker-driven drug development
• Individualized patient response prediction

Therapeutic Area	Patient Population	Precision Medicine Approach
Type 2 Diabetes	Insulin-resistant patients	Genetic variant screening
Neurological Disorders	Early-stage Alzheimer's patients	Inflammatory marker analysis

vTv Therapeutics Inc. (VTVT) - Business Model: Customer Relationships

Direct Engagement with Medical Research Community

As of Q4 2023, vTv Therapeutics maintains direct research engagement through:

• 5 active research collaboration networks
• 3 ongoing clinical trial partnerships
• Direct communication channels with 42 academic medical research institutions

Collaboration with Pharmaceutical Partners

Partner Type	Number of Active Partnerships	Collaboration Focus
Pharmaceutical Companies	2	Alzheimer's and Diabetes Research
Biotechnology Firms	3	Drug Development Collaboration

Scientific Conference and Industry Event Participation

2023 Event Participation Statistics:

• 12 international medical conferences attended
• 7 scientific presentations delivered
• Networking with 156 research professionals

Transparent Communication of Clinical Trial Progress

Communication Channel	Frequency	Reach
Press Releases	Quarterly	1,200 stakeholders
Clinical Trial Updates	Monthly	850 subscribers

Investor Relations and Shareholder Communication

Investor Engagement Metrics for 2023:

• 4 quarterly earnings calls
• 2 annual shareholder meetings
• Investor base of approximately 3,200 shareholders
• Investor relations website with 5,600 monthly unique visitors

vTv Therapeutics Inc. (VTVT) - Business Model: Channels

Direct Sales to Pharmaceutical Partners

As of 2024, vTv Therapeutics maintains direct sales channels targeting pharmaceutical partners for potential licensing and collaboration opportunities.

Partner Type	Engagement Strategy	Target Therapeutic Areas
Large Pharmaceutical Companies	Direct Licensing Discussions	Alzheimer's, Type 2 Diabetes
Biotechnology Firms	Research Collaboration	Neurodegenerative Diseases

Scientific Publications and Research Presentations

vTv Therapeutics utilizes scientific communication channels to disseminate research findings.

• Peer-reviewed journal publications: 7-10 per year
• Academic conference presentations: 5-8 annually
• Research data sharing platforms: Continuous updates

Investor Relations Websites and Financial Platforms

The company maintains comprehensive investor communication channels.

Platform	Reporting Frequency	Information Type
Corporate Website	Quarterly Updates	Financial Results, Pipeline Progress
SEC EDGAR	Mandatory Filings	10-K, 10-Q Reports

Medical Conference Exhibitions

vTv Therapeutics actively participates in medical and scientific conferences.

• Alzheimer's Association International Conference
• American Diabetes Association Scientific Sessions
• Neuroscience conferences: 3-4 exhibitions annually

Regulatory Submission Channels

Strategic regulatory engagement across key markets.

Regulatory Body	Submission Type	Current Status
FDA	IND Applications	Ongoing Clinical Trials
EMA	Clinical Trial Approvals	European Market Expansion

vTv Therapeutics Inc. (VTVT) - Business Model: Customer Segments

Pharmaceutical Research Organizations

vTv Therapeutics targets pharmaceutical research organizations with specific focus on metabolic disorder research.

Research Focus	Potential Organizations	Estimated Market Size
Metabolic Disorder Research	Top 20 Global Pharmaceutical Companies	$42.3 billion in 2023

Healthcare Providers

Primary customer segment includes specialized healthcare providers treating metabolic disorders.

• Endocrinology clinics: 3,742 specialized centers in United States
• Diabetes treatment centers: 5,216 nationwide facilities
• Annual treatment market: $327.5 billion

Patients with Specific Metabolic Disorders

Disorder Type	Patient Population	Annual Treatment Potential
Type 2 Diabetes	37.3 million patients in US	$45.8 billion market
Alzheimer's	6.7 million patients in US	$22.3 billion potential market

Medical Research Institutions

vTv Therapeutics collaborates with leading research institutions.

• Top 50 research universities engaged
• Annual research funding: $1.2 billion in metabolic disorder studies
• Collaborative research budget: $18.5 million

Biotechnology Investment Community

Investment Category	Total Investment	Potential Growth
Biotech Research Investments	$94.6 billion in 2023	7.2% projected annual growth

vTv Therapeutics Inc. (VTVT) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2022, vTv Therapeutics reported R&D expenses of $17.3 million. The company's R&D costs are primarily focused on developing treatments for Alzheimer's disease and diabetes.

Year	R&D Expenses	Percentage of Total Expenses
2022	$17.3 million	62.5%
2021	$15.6 million	58.9%

Clinical Trial Management Costs

Clinical trial expenses for vTv Therapeutics in 2022 were approximately $12.5 million, covering multiple phase trials for their key drug candidates.

• Phase 2 trials for TTP488 (Alzheimer's treatment)
• Ongoing diabetes treatment clinical studies
• Preclinical research for new drug candidates

Intellectual Property Registration

The company spent approximately $1.2 million on intellectual property registration and maintenance in 2022.

IP Category	Cost	Number of Patents
Patent Filing	$750,000	12 new patents
Patent Maintenance	$450,000	35 existing patents

Administrative and Operational Overhead

Administrative and operational costs for vTv Therapeutics in 2022 totaled $6.8 million.

• Executive compensation
• Office infrastructure
• Technology and software infrastructure
• Compliance and regulatory expenses

Marketing and Business Development

Marketing and business development expenses were $2.5 million in 2022, focusing on investor relations and potential partnership opportunities.

Marketing Activity	Expense
Investor Relations	$1.2 million
Conference and Presentation Costs	$800,000
Business Development	$500,000

vTv Therapeutics Inc. (VTVT) - Business Model: Revenue Streams

Potential Licensing Agreements

As of Q4 2023, vTv Therapeutics has not reported any active licensing agreements generating significant revenue.

Research Grants and Funding

Funding Source	Amount	Year
National Institutes of Health (NIH) Grant	$478,000	2023
Small Business Innovation Research (SBIR) Grant	$256,000	2023

Collaborative Research Partnerships

Current collaborative research partnerships as of 2024:

• University of North Carolina Neuroscience Research Partnership
• Duke University Alzheimer's Disease Research Collaboration

Future Pharmaceutical Product Sales

Revenue potential for pipeline products:

Drug Candidate	Potential Market Size	Estimated Launch Year
TTP399 (Diabetes Treatment)	$2.5 billion	2025
Azeliragon (Alzheimer's Treatment)	$3.7 billion	2026

Milestone Payments from Drug Development

Development Stage	Milestone Payment	Status
Phase II Clinical Trial Completion	$1.2 million	Achieved
Phase III Clinical Trial Initiation	$2.5 million	Pending

Total Revenue for 2023: $6.3 million